Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
DETAILED ACTION
Claims 1-8, 11, 14-19, 23-26 and 28 are currently pending in the instant application. Applicants have amended claims 3-5, 8, 11, 14, 16-18, 25-26 and 28 and canceled claims 9-10, 12-13, 20-22 and 27 in an amendment filed on August 29, 2024. Claims 1-3, 5-8, 11, 14-19, 23-26 and 28 are rejected and claim 4 is objected in this Office Action.
I. Priority
The instant application is a 371 of PCT/IN2023/050233, filed on March 10, 2023 and claims benefit of US Provisional Application 63/368,342, filed on July 13, 2022 and claims benefit of Foreign Applications INDIA 202241013165, filed on March 10, 2022 and INDIA 202241057045, filed on October 4, 2022.
II. Information Disclosure Statement
The information disclosure statements (IDS) submitted on August 29, 2024 and February 4, 2026 are in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statements have been considered by the examiner.
III. Rejections
Claim Rejections - 35 USC § 102
The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:
A person shall be entitled to a patent unless -
(a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention.
Claims 1, 2, 8 and 11 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Duan, et al. (European Journal of Medicinal Chemistry 140 (2017) 392-402). The instant invention claims
PNG
media_image1.png
850
797
media_image1.png
Greyscale
PNG
media_image2.png
547
805
media_image2.png
Greyscale
The Duan, et al. reference teaches tranylcypromine derivatives such as
PNG
media_image3.png
128
341
media_image3.png
Greyscale
(See page 395, Scheme 2) wherein Ring A is phenyl; n is 4, R1 is H; Y is phenyl; Z is C2 alkenyl; R2 is an aniline. This species of compound anticipates the genus compound of the instant invention, wherein the genus structure and its definitions are stated above.
Claims 1-3, 5-8, 11, 14-19, 23-26 and 28 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Rajagopal, et al. (US 2020/0308110 A1). The instant invention claims
PNG
media_image1.png
850
797
media_image1.png
Greyscale
PNG
media_image2.png
547
805
media_image2.png
Greyscale
The Rajagopal, et al. reference teaches cyclopropyl-amide derivatives such as
PNG
media_image4.png
82
327
media_image4.png
Greyscale
(See page 395, Scheme 2) wherein Ring A is phenyl; n is 4, R1 is H; Y is piperidine; Z is C3 alkyl thiazole; R2 is an aniline. This species of compound anticipates the genus compound of the instant invention, wherein the genus structure and its definitions are stated above.
Claim Rejections - 35 USC § 112
The following is a quotation of the second paragraph of 35 U.S.C. 112:
The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.
Claim 11 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Regarding claim 11, the phrase "preferably" renders the claim indefinite because it is unclear whether the limitations following the phrase are part of the claimed invention. See MPEP § 2173.05(d). Applicants are suggested to amend claim 11 so that the phrase including “preferably” is deleted to overcome the rejection.
Claim Rejections - 35 USC § 112
The following is a quotation of the first paragraph of 35 U.S.C. 112:
The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.
Claims 14-15, 17-19 and 23-24 are rejected under 35 U.S.C. 112(a) or 112, first paragraph, while being enabling for a method of treating or ameliorating a disease or condition mediated by MYC or LSD1 or HDAC or both LSD1 and HDAC does not reasonably provide enablement for a method of preventing or modulating these diseases or conditions or a method of treating or ameliorating a disease or condition mediated by coRest. The claim(s) contains subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention.
In In re Wands, 8 USPQ2d 1400 (1988), factors to be considered in determining whether a disclosure meets the enablement requirement of 35 U.S.C. § 112, first paragraph, have been described. They are:
1. the nature of the invention,
2. the state of the prior art,
3. the predictability or lack thereof in the art,
4. the amount of direction or guidance present,
5. the presence or absence of working examples,
6. the breadth of the claims,
7. the quantity of experimentation needed, and
8. the level of the skill in the art.
The nature of the invention
Applicants are claiming a method of treating or ameliorating a disease or condition mediated by MYC or LSD1 or HDAC or both LSD1 and HDAC. Support for the intended use is found in in vitro data for the inhibition of LSD1 and/or HDAC and in vivo data for tumor efficacy studies in a tumor model for prostate cancer in mice on pages 59-62 of the specification.
The state of the prior art and the predictability or lack thereof in the art
The state of the prior art is that the pharmacological art involves screening in vitro and in vivo to determine which compounds exhibit the desired pharmacological activities (i.e. what compounds can treat which specific disease by what mechanism). There is no absolute predictability even in view of the seemingly high level of skill in the art. The existence of these obstacles establishes that the contemporary knowledge in the art would prevent one of ordinary skill in the art from accepting any therapeutic regimen on its face.
The instant claimed invention is highly unpredictable as discussed below:
It is noted that the pharmaceutical art is unpredictable, requiring each embodiment to be individually assessed for physiological activity. In re Fisher, 427 F. 2d 833, 166 USPQ 18 (CCPA 1970) indicates that the more unpredictable an area is the more specific enablement is necessary in order to satisfy the statute. In the instant case, the instant claimed invention is highly unpredictable since one skilled in the art would recognize that in regards to therapeutic or prophylactic effects of any condition mediated by inhibiting LSD1 and/or HDAC , whether or not the condition is affected by the instant compounds' activity would make a difference.
For example, Applicants' claim is drawn to a method of preventing or modulating Alzheimer’s disease. It is the state of the art that Alzheimer’s disease is a progressive neurologic disorder that causes the brain to atrophy and brain cells to die. Alzheimer’s disease is the most common cause of dementia. Medications may temporarily improve or slow progression of symptoms. These treatments can sometimes help people with Alzheimer’s disease maximize function and maintain independence for a time. There is no treatment that cures Alzheimer’s disease or alters the disease process in the brain. The exact cause of Alzheimer’s aren’t fully understood. Researchers trying to understand the cause of Alzheimer’s are focused on the role of two proteins: Beta-amyloid and Tau proteins. Alzheimer’s disease is not a preventable condition. Evidence suggests that changes in diet, exercise and habits may lower the risk of developing Alzheimer’s disease (see URL https://www.mayoclinic.org/diseases-conditions/alzheimers-disease/symptoms-causes/syc)
Only a total of five drugs developed to improve the symptoms of Alzheimer’s disease have been approved by the FDA. The five drugs function by two different mechanisms> One is cholinesterase inhibition, which delays Alzheimer’s disease by blocking hydrolysis of the critical neurotransmitter acetylcholine. This category of drugs include donepezil (Aricept), rivastigmine (Exelon) and galantamine (Razadyne). The other one is memantine, a non-competitive N-methyl-D-aspartate (NMDA) channel blocker that reduces the activity of the neurotransmitter glutamate, which plays an important role in learning and memory by binding to the NMDA receptor. Namzaric is a combination of donepezil and memantine which reduces the levels of both acetylcholine and glutamate (see Chen, et al. Acta Pharmacologica Sinica 2017:1205-1235).
There is no absolute predictability even in view of the seemingly high level of skill in the art. The existence of these obstacles establishes that the contemporary knowledge in the art would prevent one of ordinary skill in the art from accepting any therapeutic regimen on its face.
The amount of direction or guidance present and the presence or absence of working examples
The only direction or guidance present in the instant specification is minimal. There are no working examples present for preventing any disease involving inhibiting LSD1 and/or HDAC.
Test assays and procedure are provided in the specification such as in vitro data for the inhibition of LSD1 and/or HDAC and in vivo data for tumor efficacy studies in a tumor model for prostate cancer in mice on pages 59-62.
Receptor activity is generally unpredictable and the data provided is insufficient for one of ordinary skill in the art in order to extrapolate to the other compounds of the claims. It is inconceivable as to how the claimed compounds can treat the extremely difficult diseases embraced by the instant claims.
Applicants have not provided any competent evidence or disclosed tests that are highly predictive for the pharmaceutical use of the instant compounds. Pharmacological activity in general is a very unpredictable area. Note that in cases involving physiological activity such as the instant case, “the scope of enablement obviously varies inversely with the degree of unpredictability of the factors involved.” See In re Fisher, 427 F.2d 833, 839, 166 USPQ 18, 24 (CCPA 1970).
The breadth of the claims
The breadth of the claims is a method of treating, preventing, modulating or ameliorating a disease or condition mediated by MYC or coREST or LSD1 or HDAC or both LSD1 and HDAC or a method of treatment and/or prevention of a disease or a condition mediated by both LSD1 and HDAC.
The quantity of experimentation needed and the level of the skill in the art
The quantity of experimentation needed is undue experimentation. One of skill in the art would need to determine what diseases would be benefited by the effects of inhibiting LSD1 and/or HDAC and would furthermore then have to determine which of the claimed compounds in the instant invention would provide treatment or prevention of the diseases.
The level of skill in the art is high. However, due to the unpredictability in the pharmaceutical art, it is noted that each embodiment of the invention is required to be individually assessed for physiological activity by in vitro or in vivo screening to determine which compounds exhibit the desired pharmacological activity and which diseases would benefit from this activity.
Genentech Inc. v. Novo Nordisk A/S (CA FC) 42 USPQ2d 1001, states that “a patent is not a hunting license. It is not a reward for search, but compensation for its successful conclusion” and “patent protection is granted in return for an enabling disclosure of an invention, not for vague intimations of general ideas that may or may not be workable”.
Therefore, in view of the Wands factors and In re Fisher (CCPA 1970) discussed above, to practice the claimed invention herein, a person of skill in the art would have to engage in undue experimentation to test which diseases can be treated by the compound encompassed in the instant claims, with no assurance of success.
This rejection can be overcome, for example, by amending the claim to read on the subject matter that Applicants' specification are enabled for as indicated above.
IV. Objections
Dependent Claim Objections
Dependent Claim 4 is objected to as being dependent upon a rejected based claim. To overcome this objection, Applicant should rewrite said claims in an independent form and include the limitations of the base claim and any intervening claim.
V. Conclusion
Any inquiry concerning this communication or earlier communications from the examiner should be directed to Shawquia Jackson whose telephone number is 571-272-9043. The examiner can normally be reached on 7:00 AM-3:30PM.
If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Adam Milligan can be reached on 571-270-7674. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).
/SHAWQUIA JACKSON/Primary Examiner, Art Unit 1626
Prosecution Insights